Drug holds promise for reducing coronary artery plaqueOctober 13th, 2008 - 6:30 pm ICT by ANI
Washington, Oct 13 (ANI): A commonly used drug for treating high blood pressure, olmesartan, has been found to play an effective role in reducing coronary plaque in a trial.
Titled Impact of OLmesartan on progression of coronary atherosclerosis, the trial was conducted on 247 angina patients with native coronary artery lesions.
The scientists randomly assigned patients, to receive 20-40mg/day of olmesartan or control.
The participants were then treated with a combination of ss-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents and/or statins per physician’’s guidance.
Later, Serial Intravenous Ultrasound (IVUS) examinations were performed to assess the amount of coronary plaque before, and 14 months after the start of treatment.
Patient characteristics and all IVUS measurements were identical between the two groups, at the start of the trial. However, after 14 months, IVUS showed significant decreases in measurements of plaque volume in the olmesartan group, despite similar blood pressure readings.
Also, with the help of multivariate analysis, the researchers found that olmesartan administration was one of the factors that caused the decrease in plaque volume.
“Management of plaque is a key front in the war on sudden heart attack. These results suggest a positive role in potential plaque regression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris,” said Dr. Atsushi Hirohata, Cardiovascular Medicine, the Sakakibara Heart Institute of Okayama, Okayama, Japan and lead author of the study.
The study was presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). (ANI)
- Drug may reduce coronary artery plaque - Oct 13, 2008
- Imaging techniques can identify plaques likely to cause heart attacks - Sep 25, 2009
- Everolimus-eluting stent safer, more effective than paclitaxel-eluting stent - May 06, 2010
- Coronary imaging helps track plaques that trigger heart attacks - Sep 25, 2009
- Three-pill combo for high BP launched - Nov 22, 2011
- Gout drug shows promise against angina - Jun 08, 2010
- Mother's stroke history 'can help predict daughter's heart attack risk' - Feb 02, 2011
- Low dose of beta blockers can put patients at subsequent heart attack risk - Oct 16, 2010
- Reports of problems with blood-thinner wrong: study - Aug 30, 2010
- Novel imaging technology for easy detection of vulnerable plaque - Oct 13, 2008
- Ultrasound technique better alternative to invasive angiography for diagnosing heart disease - Jun 15, 2010
- A heart pill that halves risk of death - Nov 15, 2010
- People with sleep apnea 'more likely to develop aggressive heart disease' - Dec 01, 2010
- Vaccines for heart attacks to be ready within 5 years - Apr 01, 2012
- New hope for patients at high risk of recurrences of heart disease - May 21, 2010
Tags: angina patients, angiotension, atsushi, blood pressure readings, calcium channel blockers, cardiovascular medicine, cardiovascular research foundation, coronary atherosclerosis, heart attack, heart institute, high blood pressure, native coronary artery, nitrates, okayama japan, olmesartan, patient characteristics, stable angina pectoris, sudden heart attack, transcatheter, volume management